Citicoline Controlled Release Tablets 1000 mg Manufacturer in India – Healthy Life Pharma Pvt. Ltd.

Citicoline Controlled Release Tablets 1000 mg | Manufacturer
Product image for Citicoline Controlled Release Tablets 1000 mg Manufacturer; contract manufacturing, oem & quality control.
Product Information
| Generic Name | Citicoline |
|---|---|
| Manufacturer | Healthy Life Pharma Pvt. Ltd. |
| HSN Code | 30049099 |
| Pharmacopoeia | IP / BP |
| Product Type | Tablet |
| Category | Antidementia drugs |
| Subcategory | Antidementia drugs |
| Active Ingredient | Citicoline |
| Strength | 1000 mg |
| Dosage Form | Tablet |
| Pack Size | 10 x 10 Tablets / Box (Alu-Alu / Blister) |
| Route of Administration | Oral |
| Prescription Required | Yes |
| Therapeutic Category | Antidementia drugs |
Medicine Details & Safety
| Short Description | Healthy Life Pharma invites contract and third-party manufacturing enquiries for Citicoline Controlled Release Tablets 1000 mg from pharmaceutical marketing companies, institutional buyers and brand owners. Production specifications, batch size and packaging are agreed against the approved product dossier and purchase requirements. | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Approved Uses / Indications | 1. Management of generalized tonic-clonic, focal, and absence epileptic seizures. 2. Adjunctive treatment in trigeminal neuralgia, neuropathic pain, and mood stabilization. | ||||||||||||||||||||||||
| Full Description | Healthy Life Pharma invites contract and third-party manufacturing enquiries for Citicoline Controlled Release Tablets 1000 mg from pharmaceutical marketing companies, institutional buyers and brand owners. Production specifications, batch size and packaging are agreed against the approved product dossier and purchase requirements. Product technical specifications
Product technical specifications
Manufacturing capabilities and infrastructureFor Citicoline Controlled Release Tablets 1000 mg, assess the approved formulation process, equipment suitability, batch scale and in-process controls for the Tablet presentation. Confirm environmental requirements and validated process before production.Quality control and assuranceRequest the approved finished-product specification for Citicoline Controlled Release Tablets 1000 mg, including applicable identity, assay, uniformity and performance tests for the Tablet presentation. Confirm analytical methods, acceptance criteria and batch release documentation, including COA availability.Primary and secondary packagingThe catalogue pack for Citicoline Controlled Release Tablets 1000 mg is 10 x 10 Tablets / Box (Alu-Alu / Blister). Confirm primary packaging compatibility, stability evidence, artwork, batch coding and leaflet requirements against the approved specification.Contract manufacturing and private labelSubmit the target market, strength, pharmacopoeial specification, forecast volume and brand artwork. Agree feasibility, batch size, quality agreement, production schedule and release criteria before execution. | ||||||||||||||||||||||||
| Dosage Instructions | Administer orally at regular scheduled intervals daily. Swallow whole with water; maintain consistent dosing to achieve stable therapeutic anticonvulsant plasma concentrations. | ||||||||||||||||||||||||
| Side Effects | Common: Drowsiness, fatigue, ataxia, dizziness, diplopia, nausea. Uncommon: Tremor, cognitive slowing, skin rash, mild transaminase elevation. Rare: Stevens-Johnson syndrome, hepatotoxicity, pancreatitis, aplastic anemia. | ||||||||||||||||||||||||
| Warnings and Precautions | Abrupt Discontinuation: Never stop abruptly; gradual withdrawal over weeks is required to avoid precipitating status epilepticus. Suicidal Ideation: Monitor closely for emergence of depressive mood changes or suicidal thoughts. Hepatic & Hematologic Testing: Regular blood counts and liver enzymes are recommended. | ||||||||||||||||||||||||
| Contraindications | 1. Known hypersensitivity to Citicoline or related anticonvulsant chemical structures. 2. Acute intermittent porphyria or atrioventricular conduction block. 3. Severe hepatic impairment or preexisting bone marrow depression. | ||||||||||||||||||||||||
| Drug Interactions | 1. Other Antiepileptics (Phenytoin, Carbamazepine, Valproate): Mutual metabolic induction or inhibition requiring serum monitoring. 2. Oral Contraceptives: Enzyme-inducing anticonvulsants decrease contraceptive hormone efficacy. 3. CNS Depressants & Alcohol: Marked intensification of central nervous system depression. |
Frequently Asked Questions
| Question | Answer |
|---|---|
| Can I request third-party manufacturing for Citicoline Controlled Release Tablets 1000 mg? | Submit your brand, quantity and packaging requirements for manufacturing feasibility review. |
| Which pharmacopoeial standard applies for Citicoline Controlled Release Tablets 1000 mg? | The source specification is IP / BP; confirm the required standard before contracting. |
| What quality tests are applicable for Citicoline Controlled Release Tablets 1000 mg? | Request the approved finished-product specification and batch testing plan. |
| Can packaging be customized for Citicoline Controlled Release Tablets 1000 mg? | Submit artwork and pack requirements for technical and regulatory review. |
| How do I request a manufacturing quotation for Citicoline Controlled Release Tablets 1000 mg? | Provide forecast volume, target market, strength and packaging requirements. |
